Catalyst · readout
Phase 3 TRIUMPH readouts expected 2026-2027.
Expected: Jan 1, 2026 – Dec 31, 2027
Catalyst details
- Type
- readout
- Status
- pending
- Date precision
- window
- Confidence
- company guidance
- Asset
- Retatrutide
- Company
- Eli Lilly
Dependencies
- trial-06
Source wording
“Phase 3 TRIUMPH readouts expected 2026-2027.”
Sources
- registryprimary record
A study of retatrutide (LY3437943) in participants with obesity
Eli Lilly and Company · ClinicalTrials.gov · Sep 8, 2022 · NCT05567796